VEGFC and myocardial infarction: Intraperitoneal injection of recombinant VEGFC-C156S, intramyocardial injection of microparticles loaded with VEGFC-C156S, and intraperitoneal injection of adeno-associated virus (AAV) encoding VEGFC-C156S all showed robust protective effects after myocardial infarction.